在多发性硬化症前症候群中使用抗震剂和 gabapentinoids 药物治疗:基于人口的匹配队列研究
Himali Bergeron-Vitez1, Fardowsa LA Yusuf2, Feng Zhu3
1International Collaboration on Repair Discoveries (ICORD), University of British Columbia, Vancouver, Canada; Department of Anesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
Multiple sclerosis and related disorders
|December 1, 2024
概括
与对照人群相比,患有多发性硬化症 (MS) 的人在疾病发作之前更有可能填写抗药和 gabapentinoids 的处方. 这表明在MS患者中潜在的早期神经病痛管理.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 患有多发性硬化症 (MS) 的人在疾病发作之前经常比对照组填写更多的处方,包括治疗疼痛.
- 在MS诊断之前,关于使用神经病痛相关药物的知识有限.
研究的目的:
- 为了比较接收抗发作药物或 gabapentinoid 处方的几率,在后来患上多发性硬化症的人群中,与在多发性硬化症发病之前的对照人群相比.
- 在多发性硬化症的背景下调查与神经病痛相关的早期药物治疗模式.
主要方法:
- 使用1996年至2013年的行政医疗保健数据,采用了匹配的队列研究设计.
- 该研究将4,862名多发性硬化症患者与22,669名匹配的对照人群进行了比较,将多发性硬化症发病定义为第一个与疾病相关的脱髓化事件.
- 使用多变量逻辑回归分析来确定抗/加巴类药物处方的几率.
主要成果:
- 与对照人群相比,多发性硬化症患者更有可能填写抗药物的处方 (调整后的几率比率[aOR] = 3.1).
- 病例还显示,填补 gabapentinoid 处方 (aOR = 4.1) 和 gabapentinoids 没有同时使用抗药 (aOR = 3.9) 的几率更高.
- 所有报告的赔率比率都具有统计学意义,信心区间窄.
结论:
- 与匹配的对照人群相比,患有多发性硬化症的个人在疾病发病前更有可能填写抗药和 gabapentinoids 的处方.
- 这些发现突出了早期使用这些止痛药和随后发展多发性硬化症之间的潜在关联.
相关概念视频
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
251
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
251
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
333
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
333
01:14Antiepileptic Drugs: Glutamate Antagonists
283
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
283
01:20Antiepileptic Drugs: Potassium Channel Activators
146
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
146